Latest Mental Health News

Page 7 of 13
Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.
Ada Torres
Ada Torres
28 Jan 2026
Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.
Ada Torres
Ada Torres
22 Jan 2026
Entropy Neurodynamics reports compelling Phase 2a results showing oral psilocybin dramatically reduces binge eating episodes and related psychiatric symptoms, supporting advancement of its lead IV psilocin candidate.
Ada Torres
Ada Torres
13 Jan 2026
InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.
Ada Torres
Ada Torres
9 Jan 2026
InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.
Ada Torres
Ada Torres
23 Dec 2025
TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.
Ada Torres
Ada Torres
18 Dec 2025
Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.
Ada Torres
Ada Torres
16 Dec 2025
Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.
Ada Torres
Ada Torres
16 Dec 2025
Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.
Ada Torres
Ada Torres
11 Dec 2025
InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.
Ada Torres
Ada Torres
10 Dec 2025
InhaleRx Limited has secured $427,500 from an initial tranche of its $1 million capital raise, issuing 17.1 million shares to support its inhaled therapies targeting pain and mental health conditions.
Ada Torres
Ada Torres
9 Dec 2025
InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.
Ada Torres
Ada Torres
4 Dec 2025

Browse the archive

Full archive